logo-loader

Scancell focuses on development of two critical cancer fighting assets

Last updated: 07:52 05 Feb 2024 GMT, First published: 06:47 15 Sep 2023 BST

Snapshot

  • Scancell Holdings appoints new head of development
  • Scancell: US investment bank resumes coverage with punchy price target
  • Scancell CEO hails "exciting" high response rate to melanoma treatment
lab worker

About the company

Scancell Holdings PLC is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate truly novel medicines to treat significant unmet needs in cancer and infectious disease.

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells.

In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies to redirect immune cells or drugs.

How it is doing

05 Feb 2024

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF), the developer of cancer immunotherapies, has announced key changes to its executive team. 

Investors were told Dr Sally Adams is set to retire as chief development officer to be succeeded by Dr Callum Scott, who will assume the role of head of development with immediate effect.

Scott brings with him 15 years in R&D. His last position was as technical transfer & formulation development manager with Allergy Therapeutics, which saw him leading critical chemistry, manufacturing, and controls and product development phases for Allergy's VLP Peanut project.

"Firstly, on behalf of the Scancell board, I would like to express our sincere gratitude to Sally for her expertise and support over the last 15 years, both on the board and leading clinical development," said chief executive, professor Lindy Durrant.

30 Jan 2024

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) said it is hoping to build on the significant clinical progress it has made in the first half of the financial year as it set out its "key near-term milestones".

Chief among them will be the second stage of the SCOPE study in advanced melanoma with its key asset, the oncology vaccine SCIB1. Recruitment is slated to start in the first quarter of 2024 meaning data should be available in Q3 of the calendar year.

17 Jan 2024

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) has received the go-ahead from UK medical regulator MHRA to add another group of patients to its ongoing SCOPE skin cancer trial.

This third cohort will comprise 43 advanced unresectable melanoma patients who will receive Scancell’s iSCIB1+ with doublet therapy, consisting of existing blockbuster cancer treatments ipilimumab (Yervoy) plus nivolumab (Opdivo).  

What the brokers say

04 Jan 2024

Stifel has resumed coverage of biopharmaceutical company Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) with a repeat of its 'buy' recommendation and 30p target price - a significant premium to the current 11p share price.

The American investment bank cites Scancell's successful (and significantly upsized) £11.9 million capital raise as a major source for optimism going forward.

The issue of new stock, at a 10.2% discount to the prevailing market price, extends Scancell's financial runway to mid-to-late 2025.

What management says

19 Sep 2023

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) chief executive Professor Lindy Durrant speaks to Thomas Warner from Proactive to provide an update on the initial phase of the clinical stage biopharmaceutical company's Phase 2 SCOPE trial in advanced melanoma.

Professor Durrant gives an overview of the findings so far, saying that in the initial 11 patients they have achieved an impressive 82% overall response rate, surpassing the anticipated 70%. This development could be crucial for metastatic melanoma patients, as previous studies reported only a 50% response rate.

She adds that the potential to significantly improve outcomes is especially significant given the rising cases, particularly among young women. While further confirmation is needed in a larger cohort, the data's strength suggests promising results in the broader study.

Scancell CEO hails "exciting" high response rate to melanoma treatment

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) chief executive Professor Lindy Durrant speaks to Thomas Warner from Proactive to provide an update on the initial phase of the clinical stage biopharmaceutical company's Phase 2 SCOPE trial in advanced melanoma. Professor Durrant gives an overview...

on 19/9/23